Premium
P3‐355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [ 18 F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMI‐QUANTITATIVE AND QUANTITATIVE METHODS
Author(s) -
Collij Lyduine,
Konijnenberg Elles,
Reimand Juhan,
Kate Mara,
Braber Anouk,
Alves Isadora Lopes,
Zwan Marissa D.,
Yaqub Maqsood M.,
Assema Daniëlle,
Wink Alle Meije,
Lammertsma Adriaan A.,
Scheltens Philip,
Visser Pieter Jelle,
Barkhof Frederik,
Berckel Bart N.M.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1717
Subject(s) - standardized uptake value , positron emission tomography , nuclear medicine , population , medicine , psychology , environmental health
of disease modifying treatment. Unconditional benefits were reported less frequently but include the potential for positive lifestyle changes (e.g. improved diet and exercise) and future planning. Conclusions:Physicians’ perceptions demonstrated a risk-benefit assessment of amyloid imaging in preclinical individuals. Frequently cited risks to employment and insurability highlight the need for legal protections specifically for biomarkers. The reported riskbenefit assessment will contribute to the development of standardized counseling and informed consent methods for amyloid PET imaging.